Howson Pharmaceuticals" "Amephenol amine nofowe tablets" declared for listing to be reviewed as a matter of priority.

On September 17th Howson Pharmaceuticals filed a market application for a new class of drugs, Amephenol Amine Nofowe tablets, to be included in the priority review for treatment in adult patients with chronic hepatitis B.
Amephenol amine nofovir tablet (HS-10234) is a nucleoside reverse transcriptase inhibitor, a new generation of monophosphamide monoester, is very stable in plasma, so it can provide a new type of norovir pre-drug that can improve efficacy and reduce toxicity and side effects.
chronic hepatitis B virus (hepatitis B) is a failing liver disease.
World Health Organization estimates that more than 250 million people worldwide have hepatitis B, of whom nearly 90 million live in China.
B is a global epidemic with more patients than hepatitis C and AIDS, and higher morbidity and mortality rates.
hepatitis B is the leading cause of chronic liver disease and liver transplantation, with nearly 1 million deaths linked to hepatitis B worldwide each year.
current standard treatment for hepatitis B is long-term inhibitory therapy, with a lower (not eliminated) cure rate due to the use of drugs that reduce (not eliminate) the virus. According to
Frost and Sullivan, global sales of hepatitis B treatment drugs in 2017 were $17.3 billion and $54.3 billion, respectively, and the market size of hepatitis B treatment drugs is expected to grow to $45.5 billion and $181.8 billion, respectively, by 2022.
.